Aiforia Technologies (AIFORIA) Q4 2024 earnings summary

Executive summary

• Revenue grew 19% year-over-year to EUR 2.85 million, with the clinical market now representing 50% of total revenue and a shift to multi-year contracts with large hospital districts.

• Order book increased by 118% year-over-year, reflecting strong demand for AI-assisted image analysis and expansion in Europe, North America, and Asia.

• Major deals closed with flagship hospitals and regions, including Mayo Clinic, NHS, Memorial Hospital Istanbul, Veneto, Lombardy, AP-HP Paris, Fimlab, and Castile and León.

• Expanded product portfolio with new AI models, including CE-IVDR and Mayo Clinic collaborations, and launched AiforiaⓇ Studies for preclinical research.

• Maintained strong partnerships and continued innovation in AI-driven pathology solutions.

Financial highlights

• Revenue increased by 19% year-over-year to EUR 2,852 thousand; order book reached EUR 5,165 thousand.

• EBITDA improved to EUR -8,220 thousand from -9,699 thousand; net loss narrowed to EUR -11,947 thousand.

• Cash and cash equivalents at year-end were EUR 11,496 thousand.

• Clinical business grew at approximately 150% per year over the past two years.

• Product development investment totaled EUR 5,581 thousand.

Outlook and guidance

• Targeting break-even cash flow from operations by end of 2024 and positive operating cash flow.

• Long-term goal to reach EUR 100 million in revenue by 2027, with mid-term targets of 50 key accounts and profitable business by 2027.

• Expanding regulatory-approved AI models and strategic partnerships, with major deals expected in France, Italy, Spain, UK, and Finland.

• Short-term targets include expanding clinical and preclinical offerings and forming at least three new strategic partnerships.